Evoke Pharma Inc (EVOK) Expected to Announce Earnings of -$0.22 Per Share
Wall Street analysts predict that Evoke Pharma Inc (NASDAQ:EVOK) will report earnings of ($0.22) per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Evoke Pharma’s earnings, with the lowest EPS estimate coming in at ($0.26) and the highest estimate coming in at ($0.18). Evoke Pharma posted earnings per share of ($0.18) in the same quarter last year, which would indicate a negative year over year growth rate of 22.2%. The firm is scheduled to issue its next quarterly earnings report on Wednesday, March 21st.
On average, analysts expect that Evoke Pharma will report full year earnings of ($1.00) per share for the current year, with EPS estimates ranging from ($1.03) to ($0.96). For the next fiscal year, analysts anticipate that the firm will post earnings of $0.09 per share, with EPS estimates ranging from ($0.54) to $1.16. Zacks’ EPS averages are a mean average based on a survey of research analysts that cover Evoke Pharma.
Evoke Pharma (NASDAQ:EVOK) last announced its earnings results on Tuesday, November 14th. The specialty pharmaceutical company reported ($0.34) EPS for the quarter, missing analysts’ consensus estimates of ($0.21) by ($0.13). During the same quarter in the previous year, the business posted ($0.29) earnings per share.
Shares of Evoke Pharma (NASDAQ EVOK) traded up $0.04 during trading hours on Friday, reaching $2.69. The company’s stock had a trading volume of 82,106 shares, compared to its average volume of 401,574. Evoke Pharma has a 52-week low of $1.42 and a 52-week high of $4.55.
A hedge fund recently raised its stake in Evoke Pharma stock. Vanguard Group Inc. increased its position in Evoke Pharma Inc (NASDAQ:EVOK) by 15.1% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 523,650 shares of the specialty pharmaceutical company’s stock after buying an additional 68,544 shares during the quarter. Vanguard Group Inc. owned about 3.40% of Evoke Pharma worth $1,341,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 13.64% of the company’s stock.
About Evoke Pharma
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Evoke Pharma Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma Inc and related stocks with our FREE daily email newsletter.